Marie-Lise Gougeon

USPTO Granted Patents = 14 (Patent Applications = 5)

CIPO Patents = 3

EPO Patents = 8 (Patent Applications = 16)

Average Co-Inventor Count = 4.2

ph-index = 4

Forward Citations = 62(Granted Patents)

Location History:

Clamart, FR (2013 - 2018)
Paris, FR (2018)
Antony, FR (2017 - 2022)

Company Filing History:

Institut National De La Sante Et De La Recherche Medicale

patents

3 out of 317

Assistance Publique-hopitaux De Paris

patents

4. 2 out of 103

Université Paris Diderot-Paris 7

Centre Hospitalier De Versailles

Institut Gustave Roussy

patents

9. 1 out of 132

UniversitÉ Paris Descartes

patents

10. 1 out of 67

Université Pierre Et Marie Curie

patents

11. 1 out of 1

Instituto Nazionale Per Le Malattie Infettie Irccs Lazzaro Spallanzani

patent

12. 1 out of 61

Assistance Publique - Hopitaux De Paris (aphp)

patents

where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12105095 - Assay to detect and quantitate specific antibodies for various redox forms of HMGB1 (2024-10-01),

2. 11460473 - Assay to detect and quantitate specific an antibodies for various redox forms of HMGB1 (2022-10-04),

3. 10890583 - Predictive value of-specific immune response for recurrence and disease outcome (2021-01-12),

4. 10018629 - Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planus (2018-07-10),

5. 10012655 - Method for quantitating total HMGB1 protein in biological samples (2018-07-03),

6. 9938528 - Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections (2018-04-10),

7. 9766254 - HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders (2017-09-19),

8. 9547006 - Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planus (2017-01-17),

9. 9164107 - HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders (2015-10-20),

10. 9164103 - Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence (2015-10-20),

11. 8906634 - Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence (2014-12-09),

12. 8728748 - HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders (2014-05-20),

13. 8603766 - Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence (2013-12-10),

14. 8450076 - Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence (2013-05-28),

Title: Marie-Lise Gougeon: Innovator in Biomedical Research

Introduction

Marie-Lise Gougeon is a prominent inventor based in Clamart, France. She has made significant contributions to the field of biomedical research, particularly in the study of High Mobility Group Box 1 (HMGB1) and its implications in various diseases. With a total of 14 patents to her name, her work has advanced the understanding of biomarkers and disease progression.

Latest Patents

Among her latest patents, Gougeon has developed assays to detect and quantify specific antibodies for various redox forms of HMGB1. These patents detail methods for quantifying specific antibodies contained in biological samples, such as human serum and cerebrospinal fluid (CSF). Additionally, she has created in vitro methods for assessing disease progression and identifying predisposition, prognostic, or diagnostic biomarkers related to HMGB1. Furthermore, her patents include the development of kits designed to quantify specific antibodies for at least one redox form of HMGB1.

Career Highlights

Marie-Lise Gougeon has worked with esteemed institutions such as the Institut Pasteur and the Institut National de la Santé et de la Recherche Médicale. Her research has been pivotal in advancing the understanding of HMGB1's role in various medical conditions.

Collaborations

Throughout her career, Gougeon has collaborated with notable colleagues, including Hela Saidi and Beatrice Poirier-Beaudoin. These collaborations have enriched her research and contributed to her innovative work in the field.

Conclusion

Marie-Lise Gougeon's contributions to biomedical research, particularly in the area of HMGB1, have established her as a leading inventor in her field. Her patents and collaborations reflect her commitment to advancing medical science and improving diagnostic methods.

This text is generated by artificial intelligence and may not be accurate.